Zhujiang Hospital
南方医科大学珠江医院
Listed for 14 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Zhujiang Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌11 papers led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌4 papers led
- Hepatocellular carcinoma肝细胞癌54 papers led5 open trials led
- Stomach cancer胃癌10 papers led
- Retinoblastoma视网膜母细胞瘤1 paper led
- Chordoma脊索瘤1 paper led
- Osteosarcoma骨肉瘤9 papers led
- Neuroblastoma神经母细胞瘤6 papers led
- Multiple myeloma多发性骨髓瘤2 papers led3 open trials led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病1 paper led2 open trials led
- Beta thalassaemiaβ 地中海贫血1 paper led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
- IgA nephropathyIgA 肾病2 papers led
- Hirschsprung disease先天性巨结肠5 papers led
Not listed for: Hepatoblastoma, Gastrointestinal stromal tumour, Ewing sarcoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 11 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.5%.
- Open trials led
- 0
- recruiting or about to
23 hospitals in Guangzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingGP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06455410
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen Memorial Hospital; 7 listed hospitals as study sitesFoshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led11
- Exploring lipid metabolism-associated gene biomarkers and their regulatory mechanisms in nasopharyngeal carcinoma.
- Bidirectional regulation of reactive oxygen species for radiosensitization in nasopharyngeal carcinoma.
- Mechanism of skull base osteoradionecrosis explored through laboratory assessment with propensity score-matched analysis.
- A multi-gene predictive model for the radiation sensitivity of nasopharyngeal carcinoma based on machine learning.
- Development and validation of a radiosensitivity model to evaluate radiotherapy benefits in pan-cancer.
- Homologous recombination deficiency (HRD) is associated with better prognosis and possibly causes a non-inflamed tumour microenvironment in nasopharyngeal carcinoma.
- PinX1-Promoted Autophagy Inhibits Cell Proliferation and Induces Cell Apoptosis by Inhibiting the NF-κB/p65 Signaling Pathway in Nasopharyngeal Carcinoma.
- Nasopharyngeal cancer cell-derived exosomal PD-L1 inhibits CD8+ T-cell activity and promotes immune escape.
- Exosomal LBH inhibits epithelial-mesenchymal transition and angiogenesis in nasopharyngeal carcinoma via downregulating VEGFA signaling.
- Limb-bud and heart (LBH) inhibits cellular migration, invasion and epithelial-mesenchymal transition in nasopharyngeal carcinoma via downregulating αB-crystallin expression.
- Preparation of FA-targeted magnetic nanocomposites co-loading TFPI-2 plasmid and cis-platinum and its targeted therapy effects on nasopharyngeal carcinoma.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status3
More papers found outside PubMed (not counted)11
- 1370P Long-term outcomes of paclitaxel, cisplatin, and capecitabine vs. cisplatin and fluorouracil as induction chemotherapy in nasopharyngeal carcinoma: A multicenter randomized clinical trial
- Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)
- Author response: A multi-gene predictive model for the radiation sensitivity of nasopharyngeal carcinoma based on machine learning
- Omission of concurrent chemotherapy in and out of a phase III randomized controlled trial for stage II nasopharyngeal carcinoma.
- A multi-gene predictive model for the radiation sensitivity of nasopharyngeal carcinoma based on machine learning
- A multi-gene predictive model for the radiation sensitivity of nasopharyngeal carcinoma based on machine learning
- Author response: A multi-gene predictive model for the radiation sensitivity of nasopharyngeal carcinoma based on machine learning
- Neoadjuvant docetaxel-cisplatin followed by concurrent chemoradiotherapy and adjuvant tislelizumab for locally advanced nasopharyngeal carcinoma: A multicenter, single-arm, phase II trial.
- SPP1+ tumor-associated macrophages induce radioresistance of nasopharyngeal carcinoma through crosstalk with the tumor microenvironment
- Cancer stem-like cells of nasopharyngeal carcinoma express CXCR4 and display highly invasive activity
- Retraction Note: CDK4 and miR-15a comprise an abnormal automodulatory feedback loop stimulating the pathogenesis and inducing chemotherapy resistance in nasopharyngeal carcinoma
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 4 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Guangzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led4
- Association Between Treatment-Related Adverse Event Trajectory and Prognosis in Esophageal Cancer Receiving Neoadjuvant Immunochemotherapy.
- Fungal microbiota signatures anticipate neoadjuvant immunochemotherapy outcomes in esophageal cancer.
- Comparative analysis of immune checkpoint inhibitors in first-line treatment of esophageal squamous cell carcinoma: a network meta-analysis.
- PLCD1 Suppressed Cellular Proliferation, Invasion, and Migration via Inhibition of Wnt/β-Catenin Signaling Pathway in Esophageal Squamous Cell Carcinoma.
More papers found outside PubMed (not counted)1
Cancer
Hepatocellular carcinoma
肝细胞癌Led 54 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.
14 hospitals in Guangzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 10
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingExploring the Value of Urine Proteomics-based Dynamic Surveillance for Early Recurrence After Radical Surgery for Hepatocellular Carcinoma: a Prospective Cohort Study
- Phase
- Not given
- Started
- 2025-02
- Registry
- NCT06861114
Age 18 years to 75 years (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingSingle-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
- Phase
- Phase 2/Phase 3
- Started
- 2024-11
- Registry
- NCT06644937
Age 18 years to 75 years (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingPrediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
- Phase
- Not given
- Started
- 2023-11
- Registry
- NCT06157060
Age 18 years to 75 years (registered criteria)
Led by Zhujiang Hospital; 3 listed hospitals as study sitesGuangzhou
- Not yet recruitingValue of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
- Phase
- Not given
- Started
- 2024-04
- Registry
- NCT06317896
Age 18 years to 75 years (registered criteria)
Led by Zhujiang Hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingCompare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2024-06
- Registry
- NCT06449846
Age 18 years to 75 years (registered criteria)
Led by Zhujiang Hospital; 1 listed hospital as study siteGuangzhou
- RecruitingComputer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- Phase
- Not given
- Started
- 2025-09
- Registry
- NCT07170345
Age 18 years to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai
- RecruitingA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06427941
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
- RecruitingAnlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Phase
- Phase 3
- Started
- 2023-05
- Registry
- NCT05862337
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou
- RecruitingPhase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-11
- Registry
- NCT05024214
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai
- Not yet recruitingThe Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
- Phase
- Not given
- Started
- 2026-07
- Registry
- NCT07724951
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan University; 6 listed hospitals as study sitesGuangzhou, Harbin, Nanning, Qingdao, Shanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led54
- Integrin β4-Enriched Small Extracellular Vesicle as Drug Delivery Vehicle for Targeting Pulmonary Metastasis of Hepatocellular Carcinoma.
- Biomimetic Co-delivery of Lenvatinib and FePt Nanoparticles for Enhanced Ferroptosis/Apoptosis Treatment of Hepatocellular Carcinoma.
- How to Perform Laparoscopic Right Posterior Sectionectomy when the Right Intersectional Plane is not Always Flat.
- Primary liver cancer disease burden in Cambodia during 1990-2021: a systematic analysis of datasets from the global burden of disease study 2021.
- Development and validation of a nomogram for predicting early recurrence in patients undergoing different courses of postoperative adjuvant transarterial chemoembolisation.
- STOX1 Isoform A Promotes Proliferation and Progression of Hepatocellular Carcinoma by Dual Mechanisms of Transcriptionally Upregulation of Cyclin B1 and Activation of ROS-Dependent PTEN/AKT1 Signaling.
- Identification of Tumor Antigens and Immune Subtypes in Hepatocellular Carcinoma From a Multiomics Perspective.
- Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma.
- The application of augmented reality combined with indocyanine green fluorescence for guiding laparoscopic right hemihepatectomy in the treatment of hepatocellular carcinoma.
- Nanoparticle-mediated dual targeting of stromal and immune components to overcome fibrotic and immunosuppressive barriers in hepatocellular carcinoma.
- Synchronous portal vein embolization of terminal branches with transcatheter arterial chemoembolization before planned major hepatectomy for hepatitis B virus-related hepatocellular carcinoma: a single-center retrospective cohort study.
- Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma.
- Efficacy of combined TAE, HAIC, targeted, and immunotherapy in unresectable HCC: a multicenter propensity score matching study.
- Single-Port Robotic Resection of Recurrent Hepatocellular Carcinoma in the Right Anterior Lobe: A Case Report.
- Donafenib versus sorafenib in triple therapy for unresectable hepatocellular carcinoma: a propensity score-matched multicenter analysis.
- NIR-II Photoacoustic Imaging-Guided Oxygen Delivery and Controlled Release Improves Photodynamic Therapy for Hepatocellular Carcinoma.
- ASO Author Reflections: Laparoscopic Right Posterior Sectionectomy with Preservation of Subsegment Using Digital Intelligence Liver Surgery Technologies in Patients with HCC After Conversion Therapy.
- Laparoscopic Right Posterior Sectionectomy with Preservation of Subsegment Using Augmented Reality Navigation Plus ICG Fluorescence Imaging in Patients with HCC After Conversion Therapy.
- A N7-methylguanosine modified circular RNA, circIPP2A2, promotes malignant behaviors in hepatocellular carcinoma by serving as a scaffold in modulating the Hornerin/PI3K/AKT/GSK3β axis.
- Laparoscopic anatomic segment Ⅷ resection for hepatocellular carcinoma using the augmented reality-assisted navigation and indocyanine green fluorescence imaging.
- Efficacy of Augmented Reality Combined with Indocyanine Green Fluorescence Imaging Guided Laparoscopic Segmentectomy for Hepatocellular Carcinoma.
- Perfusion of hepatocellular carcinomas measured by diffusion-derived vessel density biomarker: Higher hepatocellular carcinoma perfusion than earlier intravoxel incoherent motion reports.
- Enhanced glypican-3-targeted identification of hepatocellular carcinoma with liver fibrosis by pre-degrading excess fibrotic collagen.
- Aberrant expression of circular RNA DHPR facilitates tumor growth and metastasis by regulating the RASGEF1B/RAS/MAPK axis in hepatocellular carcinoma.
- Gadoxetic Acid-Enhanced MRI-Based Radiomics Signature: A Potential Imaging Biomarker for Identifying Cytokeratin 19-Positive Hepatocellular Carcinoma.
- Deep learning nomogram based on Gd-EOB-DTPA MRI for predicting early recurrence in hepatocellular carcinoma after hepatectomy.
- Role of exosomes in the development of the immune microenvironment in hepatocellular carcinoma.
- HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway.
- Augmented Reality Navigation System and Indocyanine Green Fluorescence Imaging Make Laparoscopic Right Anterior Sectionectomy More Precisely and Safely.
- Laparoscopic modular extended right posterior sectionectomy for hepatocellular carcinoma guided by projection plane extension from the right hepatic vein.
- Perioperative and Disease-Free Survival Outcomes after Hepatectomy for Centrally Located Hepatocellular Carcinoma Guided by Augmented Reality and Indocyanine Green Fluorescence Imaging: A Single-Center Experience.
- ASO Author Reflections: Laparoscopic in situ Anatomical Mesohepatectomy for Solitary Massive HCC Using Combined Intrafascial and Extrafascial Approaches with Indocyanine Green Navigation: A New Era of Digital Intelligent Liver Surgery.
- Laparoscopic in Situ Anatomical Mesohepatectomy for Solitary Massive HCC Using Combined Intrafascial and Extrafascial Approaches With Indocyanine Green Navigation (with Video).
- A stratification model of hepatocellular carcinoma based on expression profiles of cells in the tumor microenvironment.
- Identification of chromosomal instability-associated genes as hepatocellular carcinoma progression-related biomarkers to guide clinical diagnosis, prognosis and therapy.
- Low concentration triphenyl phosphate fuels proliferation and migration of hepatocellular carcinoma cells.
- Deep convolutional neural network for preoperative prediction of microvascular invasion and clinical outcomes in patients with HCCs.
- Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy.
- Histone Acetylation Regulator-Mediated Acetylation Patterns Define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma.
- Actin-related protein 2/3 complex subunit 2-enriched extracellular vesicles drive liver cancer metastasis.
- LECT2: A pleiotropic and promising hepatokine, from bench to bedside.
- Targeted-detection and sequential-treatment of small hepatocellular carcinoma in the complex liver environment by GPC-3-targeted nanoparticles.
- A microenvironment-responsive FePt probes for imaging-guided Fenton-enhanced radiotherapy of hepatocellular carcinoma.
- Smp24, a Scorpion-Venom Peptide, Exhibits Potent Antitumor Effects against Hepatoma HepG2 Cells via Multi-Mechanisms In Vivo and In Vitro.
- Plasmonic-doped melanin-mimic for CXCR4-targeted NIR-II photoacoustic computed tomography-guided photothermal ablation of orthotopic hepatocellular carcinoma.
- Comprehensive analysis of an immune-related ceRNA network in identifying a novel lncRNA signature as a prognostic biomarker for hepatocellular carcinoma.
- Minimally invasive photothermal ablation assisted by laparoscopy as an effective preoperative neoadjuvant treatment for orthotopic hepatocellular carcinoma.
- Identification and Characterization of Alcohol-related Hepatocellular Carcinoma Prognostic Subtypes based on an Integrative N6-methyladenosine methylation Model.
- Anlotinib followed by transarterial chemoembolization and radiofrequency ablation is a safe and effective initial treatment for hepatocellular carcinoma patients with portal vein tumor thrombus: A retrospective case series study.
- Efficacy of Postoperative Adjuvant Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Patients with Mesenchymal Circulating Tumor Cell.
- A multifunctional targeted nanoprobe with high NIR-II PAI/MRI performance for precise theranostics of orthotopic early-stage hepatocellular carcinoma.
- Metabolic syndrome cannot mask the changes of faecal microbiota compositions caused by primary hepatocellular carcinoma.
- ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma.
- Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status22
- Exploring the Value of Urine Proteomics-based Dynamic Surveillance for Early Recurrence After Radical Surgery for Hepatocellular Carcinoma: a Prospective Cohort Study
- Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
- Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
- Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
- Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
- A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation
- Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial
- A Multicenter RCT Study of 3DV Technology in the Diagnosis and Treatment of PLC
- The Evaluation of Surgical Decisions and Prognosis of the Radiomics and Watson Artificial Intelligence in Patients With Hepatocellular Carcinoma
- CT Imaging for Guiding PA-TACE for HCC
- Application of Watson for Oncology in Hepatocellular Carcinoma Surgery
- The Application of Indocyanine-Green(ICG) Fluorescence Imaging in Hepatocellular Carcinoma
- Impact of Three-dimensional Visualization on Operation Strategy and Complications for Complex Hepatic Carcinoma
- The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
- Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
- A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
- Radiomics Subtyping to Guide Surgery vs. Maintenance Therapy After HCC Downstaging
- Sirolimus-based Immunosuppression Treatment Regimen for Liver Transplantation
Cancer
Stomach cancer
胃癌Led 10 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.1%.
- Open trials led
- 0
- recruiting or about to
16 hospitals in Guangzhou for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06427941
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led10
- YTHDF2-mediated m6A modification of ONECUT2 promotes stemness and oxaliplatin resistance in gastric cancer through transcriptionally activating TFPI.
- Evaluation of different lymph node classification systems as independent prognosticators in gastric signet ring cell carcinoma.
- Fusobacterium nucleatum in tumors: from tumorigenesis to tumor metastasis and tumor resistance.
- Technical variety of anastomotic techniques used in proximal gastrectomy with double-tract-reconstruction - a narrative review.
- KAT2A Promotes the Succinylation of PKM2 to Inhibit its Activity and Accelerate Glycolysis of Gastric Cancer.
- Causal association between metabolites and upper gastrointestinal tumors: A Mendelian randomization study.
- Development and Validation of Prognostic Nomograms Based on Lymph Node Ratio for Young Patients with Gastric Cancer: A SEER-Based Study.
- Evaluating the efficacy and microenvironment changes of HER2 + gastric cancer during HLX02 and Endostar treatment using quantitative MRI.
- Case Report: Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery.
- Comprehensive analysis of tumor mutation burden and immune microenvironment in gastric cancer.
All its trials on ClinicalTrials.gov, any status6
- A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China
- To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
- Acupuncture for QoL and Symptoms in Gastric Cancer During Adjuvant Chemotherapy
- Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis
Cancer
Retinoblastoma
视网膜母细胞瘤Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Guangzhou for retinoblastoma196 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Cancer
Chordoma
脊索瘤Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Guangzhou for chordoma88 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Osteosarcoma
骨肉瘤Led 9 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
33 hospitals in Guangzhou for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led9
- Long noncoding RNA DHRS4 antisense RNA 1 suppresses osteosarcoma cell proliferation and promotes apoptosis through a competitive endogenous RNA mechanism.
- 3D-Printed Magnesium Peroxide-Incorporated Scaffolds with Sustained Oxygen Release and Enhanced Photothermal Performance for Osteosarcoma Multimodal Treatments.
- Disulfidoptosis-related molecular subtypes and prognostic model for optimizing drug therapy in metastatic osteosarcoma patients.
- Cu-Tremella fuciformis polysaccharide-based tumor microenvironment-responsive injectable gels for cuproptosis-based synergistic osteosarcoma therapy.
- Case report: A case of primary renal osteosarcoma.
- Cirsiliol induces autophagy and mitochondrial apoptosis through the AKT/FOXO1 axis and influences methotrexate resistance in osteosarcoma.
- Characterization of the Tumor Microenvironment in Osteosarcoma Identifies Prognostic- and Immunotherapy-Relevant Gene Signatures.
- Circular RNA 0102049 suppresses the progression of osteosarcoma through modulating miR-520g-3p/PLK2 axis.
- Circular RNA circ_001422 promotes the progression and metastasis of osteosarcoma via the miR-195-5p/FGF2/PI3K/Akt axis.
Earlier papers (2016–2020)8
- Therapeutic potential of targeting HSPA5 through dual regulation of two candidate prognostic biomarkers ANXA1 and PSAT1 in osteosarcoma.
- Knockdown of TBRG4 suppresses proliferation, invasion and promotes apoptosis of osteosarcoma cells by downregulating TGF-β1 expression and PI3K/AKT signaling pathway.
- AgBiS2 nanoparticles with synergistic photodynamic and bioimaging properties for enhanced malignant tumor phototherapy.
- Cadmium chloride enhances cisplatin sensitivity in osteosarcoma cells by reducing FOXM1 expression.
- Enhancing Osteosarcoma Killing and CT Imaging Using Ultrahigh Drug Loading and NIR-Responsive Bismuth Sulfide@Mesoporous Silica Nanoparticles.
- Zero-Dimensional Carbon Dots Enhance Bone Regeneration, Osteosarcoma Ablation, and Clinical Bacterial Eradication.
- Hypoxia-inducible microRNA-488 regulates apoptosis by targeting Bim in osteosarcoma.
- Porous nano-hydroxyapatite/collagen scaffold containing drug-loaded ADM-PLGA microspheres for bone cancer treatment.
Cancer
Neuroblastoma
神经母细胞瘤Led 6 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.5%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
23 hospitals in Guangzhou for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led6
- Identification of key genes related to cancer associated fibroblasts in neuroblastoma: A comprehensive bioinformatics approach.
- Integrated machine learning-driven disulfidptosis profiling: CYFIP1 and EMILIN1 as therapeutic nodes in neuroblastoma.
- SYNJ1 rescues motor functions in hereditary and sporadic Parkinson's disease mice by upregulating TSP-1 expression.
- Machine learning methods revealed the roles of immune-metabolism related genes in immune infiltration, stemness, and prognosis of neuroblastoma.
- The m6A methyltransferase METTL3 affects cell proliferation and migration by regulating YAP expression in Hirschsprung disease.
- GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients.
Earlier papers (2016–2020)3
- Tristetraprolin destabilizes NOX2 mRNA and protects dopaminergic neurons from oxidative damage in Parkinson's disease.
- Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling.
- Endoscopic surgery for primary sinonasal malignancies: Treatment outcomes and prognostic factors.
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 2 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.1%.
14 hospitals in Guangzhou for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 5
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingIntestinal Flora and Immunity in Monoclonal Gammopathy Patients
- Phase
- Not given
- Started
- 2024-05
- Registry
- NCT06539832
Age 45 years to Not stated (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingCharacteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT06690593
Age 45 years to Not stated (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingScreening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis
- Phase
- Not given
- Started
- 2023-01
- Registry
- NCT05686447
Age not stated (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingA Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07477587
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou
- Not yet recruitingClinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07569757
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status9
- Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy
- Intestinal Flora and Immunity in Monoclonal Gammopathy Patients
- Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis
- A Cross-sectional Study on the Positive Rate of M Protein Based on a Highly Sensitive Serum M Protein Detection Method.
- CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- A Study of Ninlaro in Real World Clinical Practice in China
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病Led 1 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.4%.
8 hospitals in Guangzhou for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingCD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Registry
- NCT07072494
Age 14 years to 80 years (registered criteria)
Led by Zhujiang HospitalGuangzhou
- Not yet recruitingClinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia
- Phase
- Early phase 1
- Started
- 2026-08
- Registry
- NCT07696481
Age 3 years to 75 years (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingInaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- Phase
- Not given
- Started
- 2024-06
- Registry
- NCT06450067
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status7
- Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia
- CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study
- CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma
- Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL
- Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
- A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Blood disorders
Beta thalassaemia
β 地中海贫血Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
23 hospitals in Guangzhou for beta thalassaemia157 hospitals in China for beta thalassaemia
No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
13 hospitals in Guangzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
IgA nephropathy
IgA 肾病Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
20 hospitals in Guangzhou for IgA nephropathy346 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status1
Other diseases
Hirschsprung disease
先天性巨结肠Led 5 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 3.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Guangzhou for Hirschsprung disease82 hospitals in China for Hirschsprung disease
No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led5
- H3K36 methyltransferase SMYD2 affects cell proliferation and migration in Hirschsprung's disease by regulating METTL3.
- Hirschsprung's disease: m6A methylase VIRMA suppresses cell migration and proliferation by regulating GSK3β.
- Circular RNA MTCL1 targets SMAD3 by sponging miR-145-5p for regulation of cell proliferation and migration in Hirschsprung's disease.
- The m6A methyltransferase METTL3 affects cell proliferation and migration by regulating YAP expression in Hirschsprung disease.
- Plasma exosomal miR-199a-3p downregulates cell proliferation and migration in Hirschsprung's disease by targeting mTOR.
Getting in touch
Name card to show staff or a driver
南方医科大学珠江医院
Zhujiang Hospital
广州
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Zhujiang Hospital of Southern Medical University; ZhuJiang Hospital; Southern Medical University/Zhujiang Hospital; Zhujiang Hospital Southern Medical University; Southern Medical University Zhujiang Hospital; Zhujiang Hospital of Southern Medcal University; Pediatric Center of Zhujiang Hospital; Otorhinolaryngology of Zhujiang Hospital